Kisspeptin-10

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Kisspeptin-10 is not an FDA-approved drug and has no authorized clinical use outside registered investigational studies. It was included in the FDA's 503A Category 2 list of bulk drug substances that raise significant safety concerns for compounding pharmacies. Critically, kisspeptin-10 was NOT among the 12 peptides removed from Category 2 in April 2026 (effective ~April 22–23, 2026). Those 12 removals covered BPC-157, TB-500, Semax, Epitalon, KPV, MOTs-C, Emideltide, GHK-Cu, Melanotan II, LL-37, PEG-MGF, and Dihexa Acetate. Kisspeptin-10 therefore remains a restricted Category 2 substance and may not be compounded under section 503A. Sale for human consumption is not authorized.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Kisspeptin-10

Origin

Kisspeptin-10 (KP-10) is the minimal bioactive C-terminal decapeptide derived by proteolytic processing of kisspeptin-54, the primary secreted product of the KISS1 gene. The full-length kisspeptin-54 is expressed in hypothalamic arcuate and anteroventral periventricular nuclei; proteolysis yields the smaller fragments KP-14, KP-13, and KP-10, all of which share the conserved C-terminal RF-amide motif required for GPR54 binding. KP-10 retains complete agonist activity at KISS1R despite its short length and is widely used in research because of its synthetic accessibility. It carries CAS 374675-21-5, PubChem CID 25240297, and ChEMBL ID CHEMBL376756.

Registry IDs

PubChem CID

25240297

CAS

374675-21-5

InChIKey

RITKWYDZSSQNJI-INXYWQKQSA-N

ChEMBL

CHEMBL376756

Molecular formula

C63H83N17O14

Molar mass

1302.4 g/mol

Monoisotopic

1301.63054039 Da

InChIKey

RITKWYDZSSQNJI-INXYWQKQSA-N

Appearance

White to off-white lyophilized powder

Solubility

Soluble in water and dilute acidic aqueous solutions (e.g., 0.1% acetic acid); l…

Sequence not available in current seed.

Stability: KP-10 is susceptible to proteolytic degradation in biological fluids, particularly by endopeptidases; stability in aqueous solution is pH-dependent and limited

Vial sizes

5 mg

Purity grades

≥98% HPLC

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Kisspeptin-10 binds the Gq/11-coupled receptor KISS1R (GPR54) expressed on hypothalamic GnRH neurons, triggering phospholipase C activation, inositol trisphosphate-mediated intracellular calcium release, and protein kinase C activation that depolarizes GnRH neurons and drives pulsatile GnRH secretion
• This upstream stimulation of the hypothalamic pulse generator produces dose-dependent increases in circulating LH and, to a lesser degree, FSH within minutes of administration in humans, with downstream effects on gonadal steroid production
• Kisspeptin neurons themselves integrate permissive metabolic and hormonal cues — including leptin, estrogen, and testosterone negative-feedback — thereby serving as a critical gatekeeper between systemic energy and reproductive status and the GnRH axis
• Loss-of-function mutations in KISS1 or GPR54 in humans cause complete hypogonadotropic hypogonadism and pubertal failure, confirming the pathway's essential role in reproductive competence

Pharmacokinetics (ADME)

Half-life

Approximately 4 minutes (plasma half-life, IV administration, human studies); substantially shorter than kisspeptin-54 (~28 min terminal half-life)

Clearance

Rapid proteolytic degradation, likely by endopeptidases including neprilysin; subcutaneous bioavailability is limited by local tissue peptidase activity — subcutaneous bolus has shown inconsistent LH stimulation in women

PK–PD note: The very short plasma half-life of KP-10 limits its utility for sustained stimulation compared with kisspeptin-54 or continuous infusion paradigms. In research studies, IV bolus reliably evokes LH res…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Velmurugan H, et al. Kisspeptin and its Current Clinical Status—A Systematic Review. Curr Med Chem. 2025;32(7):1313-1322. — Systematic review of kisspeptin clinical status
• Varikasuvu SR, et al. Circulatory metastin/kisspeptin-1 in polycystic ovary syndrome: a systematic review and meta-analysis with diagnostic test accuracy. Reprod Biomed Online. 2019;39(4):685-697. — Systematic review and meta-analysis with diagnostic test accuracy
• Siahaan SC, et al. Serum kisspeptin levels in women with polycystic ovary syndrome: A systematic review and meta-analysis. Med J Malaysia. 2026;81(2):321-326. — Systematic review and meta-analysis
• Araújo BS, et al. Kisspeptin Influence on Polycystic Ovary Syndrome—a Mini Review. Reprod Sci. 2020;27(2):455-460. — Systematic review (mini review tag)
• Navarro VM. Metabolic regulation of kisspeptin—the link between energy balance and reproduction. Nat Rev Endocrinol. 2020;16(8):407-420. — High-impact narrative review in Nature Reviews Endocrinology
• Li Z, et al. Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src. Nat Commun. 2024;15(1):1300. — Primary mechanistic study elucidating GPR54→Dusp18→Src pathway

5 registered trials — 0 currently recruiting.

Phase 3
NCT03286517
Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.

COMPLETED

Phase 1
NCT05456854
Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

WITHDRAWN

Phase 3
NCT03315325
Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men

COMPLETED

Phase 1
NCT04532801
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

WITHDRAWN

Phase 3
NCT03771326
KP-10 and Insulin Secretion in Men

COMPLETED

Summary (literature)

In published human pharmacology studies involving IV and infusion administration of kisspeptin-10 and the related kisspeptin-54, the peptide was generally well tolerated over short-term exposure. Reported adverse effects were mild and transient, including flushing and headache; n…

WADA status

Not specifically listed by name on the WADA 2026 Prohibited List; however, as a peptide that stimulates endogenous LH and testosterone secretion, KP-10 would pl…

Dominant research route: IV

IV bolus (0.3–10 nmol/kg) and IV infusion (0.1–1.0 nmol/kg/h for 3 h) administered to healthy men and women; LH/FSH measured; plasma half-life ~3.8 (men) and 4.1 (women) min (human)

Bioavailability: Rapid systemic distribution with very short plasma half-life (~3.8–4.1 min) due to proteolytic degradation; GnRH was ~3-fold more potent than kisspeptin-10 at matched IV infusion doses in healthy men

Most-studied route; IV bolus stimulated LH/FSH in men and in preovulatory-phase women but not follicular-phase women. Direct IV comparison of kisspeptin-10 vs kisspeptin-54 vs GnRH in healthy men (n=5/group).

SC bolus (up to 32 nmol/kg) administered to healthy women during follicular phase (n=4–5) (human)

Bioavailability: SC bolus of kisspeptin-10 (up to 32 nmol/kg) failed to significantly stimulate gonadotropin release in follicular-phase women, in contrast to IV bolus effects in men/preovulatory women

Limited SC data; the one cited SC bolus study in follicular-phase women showed no significant gonadotropin response, possibly related to the ~6-fold shorter half-life of kisspeptin-10 vs kisspeptin-54.

Randomized, double-blind, crossover, placebo-controlled intranasal administration (3.2–25.6 nmol/kg in healthy men n=12; 12.8 nmol/kg in women with hypothalamic amenorrhoea n=5) — note: conducted with kisspeptin-54, not kisspeptin-10 (human)

Bioavailability: Intranasal kisspeptin-54 dose-dependently increased plasma kisspeptin at 6.4–25.6 nmol/kg (p<0.01 vs placebo), with maximal rises within 15–30 min; LH rose dose-dependently at 3.2–12.8 nmol/kg, peaking 30–45 min post-dose

Intranasal route has been studied in humans but with the longer isoform kisspeptin-54, not kisspeptin-10 specifically; authors note current therapeutic application is otherwise limited to SC/IV. Intranasal KP-10 data not identified.

Central (intracerebroventricular) and peripheral (intraperitoneal) administration of kisspeptin-10 stimulating HPG axis in rodents (animal)

Bioavailability: Both central and peripheral administration of kisspeptin-10 stimulated the hypothalamic-pituitary-gonadal axis in rodents, with effect abolished by preadministration of a GnRH antagonist

Preclinical mechanistic work establishing that kisspeptin-10 acts upstream of GnRH; rodent ICV/IP data, not human.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $5.70 · median $6.00 · p75 $8.60 · 7 researched vendors

Legit, COA-backed band: $5.20–$8.60/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$52

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Independent third-party HPLC testing (Janoshik Analytical) of research-grade kisspeptin-10 lots reported purities of ~98.7% to ~99.6% (e.g., 98.724% HPLC purity with mass-spec identity confirmation; 99.579% on a separate batch).

Independent labs cited for this compound

No FDA recalls, market withdrawals, or safety alerts specific to kisspeptin-10 were found in FDA's Recalls/Enforcement Reports databases as of search date. Kisspeptin-10 is not an FDA-approved drug and is not a component of any approved product, so product-specific recall events are not expected.

Buyer red-flag checklist

• Kisspeptin-10 is not FDA-approved and is not a component of any FDA-approved drug; no USP/NF monograph exists.
• FDA's 503A bulks evaluation found kisspeptin-10 is NOT well characterized: likely impurities, aggregates, and variants were not described in the nomination or public literature.
• FDA raised immunogenicity concerns for injectable kisspeptin-10 due to the longer amino acid chain and uncharacterized peptide-related impurities/aggregates.
• Nonclinical data flagged tachyphylaxis with continuous high-dose administration and pro-atherosclerotic signals of unclear clinical relevance.
• Gray-market research-grade kisspeptin-10 is sold online without drug-product manufacturing oversight; FDA warns unapproved new drugs 'may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.'
• No compound-specific FDA import alert or recall was located, but unapproved peptide bulk substances are subject to general FDA compounding enforcement.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent aggregate underdosing prevalence data specific to kisspeptin-10 was located from Janoshik/MZ Biolabs/Finnrick public aggregates. FDA noted that compounded/unapproved peptide products 'may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether,' but no kisspeptin-10-specific underdosing quantification was found.

• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Prohibited at all times — S2.2.1 Kisspeptin and its agonist analogues (added as a named example to the WADA Prohibited List effective January 1, 2024; continued on the 2025 List).

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• self-selection toward PSSD/post-finasteride communities
• self-experimentation often without baseline/serial hormone labs
• vendor-affiliated aggregator content present
• small de-identified author mass; anecdotal
• route/dose heterogeneity limits comparability

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

10-amino-acid C-terminal kisspeptin fragment that acts as a full GPR54/KISS1R agonist to potently stimulate pulsatile GnRH and LH release in humans. Approximately 305 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Research use only; FDA-flagged (fda19); remains on 503A Category 2 bulk drug substances list as of May 2026. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet